Latest Health News
WHO Warns US Withdrawal Risks Global Safety
The World Health Organization issued a detailed rebuttal stating the US withdrawal from WHO endangers global health security, defending its rapid COVID-19 response from initial Wuhan reports in 2019. WHO highlighted its transparent information sharing, expert convening, and guidance on masks and vaccines without mandates.
The agency hopes for US re-engagement despite the exit effective January 22, 2026.
US Officially Exits WHO After Controversial Reforms
The United States ended its WHO membership on January 22, 2026, following a year of polemic health policy decisions. This move aligns with criticisms of WHO's COVID-19 handling, prompting the agency's strong defense.
Global cooperation on pandemics, including the new Pandemic Agreement, is now at risk.
Donor Cuts to Global Fund Threaten Right to Health
Human Rights Watch warned on January 22, 2026, that donor pledges of $11.85 billion fall $6.15 billion short of the Global Fund's $18 billion target for 2026-2028, risking AIDS, TB, and malaria services. US pledged $4.6 billion but broader aid cuts have caused over 740,000 deaths and disrupted care for marginalized groups in Indonesia, Laos, and Nepal.
HRW urges closing the gap to protect rights-based services.
Scientists Warn of Rising Global Threat from Free-Living Amoebae
Researchers highlight free-living amoebae in soil and water as a growing health danger, surviving heat, chlorine, and acting as reservoirs for bacteria and viruses like the brain-eating amoeba. Climate change and poor water systems exacerbate spread, with calls for One Health surveillance and better diagnostics published January 25, 2026.
Urgent integrated public health and environmental strategies are needed.
Gedatolisib Gains FDA Priority Review for Advanced Breast Cancer
Gedatolisib showed significant progression-free survival benefits in the VIKTORIA-1 trial for advanced breast cancer, earning FDA priority review. This PI3K/mTOR inhibitor represents a key oncology breakthrough.
Updated data signal promising targeted therapies.
Amivantamab Advances in Metastatic Colorectal Cancer
OrigAMI-1 trial data presented at 2026 ASCO GI Symposium show amivantamab with FOLFOX/FOLFIRI achieving notable ORR and PFS in metastatic CRC, overcoming first-gen EGFR inhibitor resistance. This bispecific antibody marks a shift in treatment paradigms.
Further results support its potential.
FDA Grants Breakthrough Designation to Sofetabart Mipitecan for Ovarian Cancer
Sofetabart mipitecan, a FRα-targeted ADC, received FDA breakthrough therapy status for platinum-resistant ovarian cancer based on promising efficacy. This exatecan-payload therapy addresses unmet needs in advanced disease.
Approval could transform outcomes.
Epcoritamab Improves PFS in Relapsed/Refractory DLBCL
Phase 3 EPCORE DLBCL-1 topline results show subcutaneous epcoritamab monotherapy significantly improves PFS (HR 0.74) in transplant-ineligible R/R DLBCL patients. The global study involved 483 patients, mostly with ≥2 prior therapies.
This advances bispecific antibody use in lymphoma.
CaAKG Molecule Shows Promise in Restoring Alzheimer's Memory
A natural aging molecule, CaAKG, improved synaptic plasticity, memory signaling, and neuron protection in Alzheimer's models, potentially aiding cognitive aging. Levels decline with age, suggesting geroprotective strategies over symptom treatment.
Researchers see it complementing existing therapies safely.
MSF Blocked from Gaza: Staff and Supplies Denied Entry
Since January 1, 2026, MSF reports all international staff arrivals to Gaza denied and supplies blocked, hindering medical care in occupied Palestinian territory. This exacerbates humanitarian health crises.
Continuation of care is severely threatened.
Colorblindness May Hide Early Bladder Cancer Sign
Stanford study finds blood in urine, the earliest bladder cancer sign, may be invisible to colorblind individuals, complicating detection. This underscores need for accessible screening methods.
Awareness can improve early diagnosis.
Grant Funds Lung Cancer Enzyme Research
University of Cincinnati's Tom Cunningham received $150,000 from Lung Cancer Research Foundation to neutralize KRAS-mutated lung cancer growth enzyme complex. This two-year project targets vital cancer pathways.
Advances could benefit many patients.